

NIMGenetics expands in Europe with the acquisition of Gene Predictis
The Spanish biotech buys the Swiss diagnostic company specialised in precision medicine

Madrid, 13th February 2023 - **NIMGenetics**, a leading Spanish biotech company in the field of human genetic diagnostics, continues its expansion in Europe with the acquisition of the Swiss *diagnostic company* **Gene Predictis**, a leader in the field of preventive health and precision medicine.

This acquisition reinforces **NIMGenetics'** firm intent to its international expansion, with a focus on Central European markets. The synergies of both portfolios, as well as customer growth for both companies, will place **NIMGenetics** at the forefront of the genetic diagnostics market in Europe.

Gene Predictis' location in the EPFL Innovation Park in Lausanne (Ecole Polytechnique Fédérale de Lausanne) positions the Spanish biotech in a context with a strong innovative component, within an environment focused on the biotech, pharmaceutical and food tech industries.

Enrique Samper, co-founder and CEO of **NIMGenetics**, believes that "this acquisition will boost our expansion in Europe and usher in a new phase of development marked by future strategic alliances".

Gene Predictis CEO, Goranka Tanackovic, describes the integration into the group as "a great opportunity to expand our activity internationally, and to focus on our main areas of expertise".

Apposite Capital, majority investor in **NIMGenetics**, says the deal demonstrates the company's ability to lead the market by adding partner firms such as **Gene Predictis**, aligned with its existing offering of high-quality genomic products and services.

BDO, Pinsent, Avest, BAT Law and Kellerhals-Carrard advised on the transaction.

About NIMGenetics (www.nimgenetics.com)

NIMGenetics is a Spanish multinational biotech specialised in the design and commercialisation of clinical genetic diagnosis products and services, that supports specialists at all stages of the diagnostic process. Its cutting-edge diagnostic services include, among others, Triso**NIM**[™], a fetal DNA test, Exo**NIM**[™], a platform for whole exome sequencing, and Geno**NIM**[™], a comprehensive tool for genome sequencing. In addition to Spain, **NIMGenetics** is currently present in Portugal, Mexico and Brazil, serving customers worldwide.

About Gene Predictis (www.genepredictis.com)

Gene Predictis has a long track record in the interpretation of complex genetic data, with proprietary algorithms, as well as in the development of clinical diagnostic tools in the field of preventive genetics and pharmacogenomics. It also has state-of-the-art disruptive technologies, as well as a broad portfolio of services in the areas of genetics, microbiology and epidemiology.